Codexis, Inc. 2026 2. Çeyrek Kazanç Görüşmesi Özeti

Codexis, Inc. Q2 2026 Earnings Call Summary

Moby Intelligence

Wed, August 12, 2026 at 4:44 AM GMT+3 3 min read

• CDXS +8.11%

Strategic Performance and Operational Context

Our analysts just identified a stock with the potential to be the next Nvidia. Tell us how you invest and we'll show you why it's our #1 pick. Tap here.

• Management attributes the return to growth in the pharma biocatalysis business to a renewed trend of product approvals, including four new commercial products in 2026 and one significant label expansion.

• The ECOsynthesis platform is being positioned as a disruptive solution to a projected 30-fold increase in siRNA demand by 2035, which management expects will create a manufacturing bottleneck within three years.

• Strategic focus has shifted toward industrializing ECOsynthesis, moving from R&D milestones to demonstrating the scale and performance metrics required for broad customer adoption.

• The company successfully raised $25 million in net proceeds through equity financing, which management states provides the stability needed to execute long-term strategic goals.

• Operational efficiency improved through controlled spending, resulting in lower R&D and SG&A expenses primarily driven by reduced headcount and lower employee-related costs.

• Management highlighted the competitive advantage of their engineered enzymes, which offer unprecedented stereochemical control that traditional solid-phase organic synthesis methods cannot easily replicate.

Strategic Outlook and Guidance Assumptions

• Revenue guidance for 2026 remains at $70 million to $76 million, with management assuming a heavy weighting toward the second half of the year based on historical quarterly trends.

• Cash runway is now projected to fund operations and capital expenditures through 2028, including the full build-out costs for the new GMP manufacturing facility.

• The company expects to reach a 500-gram pilot scale for siRNA production by the end of 2026, with a subsequent goal of achieving kilogram-scale production before the GMP facility becomes operational.

• Gross margins for the full year 2026 are now expected to reach the high 60s, driven by a shift in product mix toward more profitable, recently approved enzymes.

• Management anticipates that the biocatalysis business could sustain high single-digit growth over the next 5 to 7 years as the current pipeline of 15 Phase II/III programs matures.

Strategic Initiatives and Risk Factors

• Construction of a $25 million GMP manufacturing facility is planned to begin following the approval of the building permit application., which is strategically intended to provide clinical trial material and support customer IND filings.

• Management introduced 'Starterless ECOsynthesis,' a novel R&D-stage capability that could further reduce manufacturing costs by initiating synthesis from a single nucleotide.

• A potential manufacturing bottleneck is flagged for the industry as large Phase 3 cardiovascular trials conclude, which management believes will force a shift toward more capital-efficient technologies like ECOsynthesis.

• The company is currently in negotiations for a long-term commercial contract with a lead CDMO partner following a successful small-scale technology transfer and assessment.

Q&A Highlights

Customer reaction to stereochemistry and starterless technology data

One stock. Nvidia-level potential. 30M+ investors trust Moby to find it first. Get the pick. Tap here.

• Management reported significant excitement from customers regarding stereochemical control, leading to new engagements with partners focused on both therapeutic potency and product quality.

• The new starterless capability has re-engaged past customers who are now interested in testing the technology due to its potential for lower costs and simpler operations.

Revenue cadence and confidence in second-half weighting

• The projected second-half revenue step-up is supported by a diverse base of business, improving trends in the core biocatalysis segment, and strong leads in the ECOsynthesis pipeline.

• Management noted that while commercial launch orders can be lumpy and unpredictable due to varying customer stockpiling strategies, the overall trend remains positive.

Scalability of ECOsynthesis relative to industry demand

• Codexis aims to scale from hundreds of grams to kilogram levels, with the potential to step up 10x further through strategic partnerships.

• Management estimates the ECOsynthesis platform is approximately 70% more capital efficient than traditional 'stainless steel' facilities, which cost roughly $1 billion per metric ton of annual capacity.

Technical hurdles in scaling to kilogram production

• Key challenges include optimizing 'classic' scale parameters such as flow rates, temperature control, and the configuration of immobilized enzymes within a simple process flow.

• The enzymes must be engineered to be robust enough to tolerate different synthetic building blocks and maintain high performance over extended operation times.